Aradigm

 

HomeAboutProductsTechnologiesInvestorsCareers

 

 

Scientific Publications

Pipeline

ARD-3100/3150 (Pulmaquin®, Lipoquin®)

ARD-1100

ARD-1600

Other Applications

Aradigm’s scientists have published extensively on aerosol formulation and pulmonary drug delivery. Excerpts from their bibliographies are cited below.

Inhaled Ciprofloxacin
Cipolla D. et al. Development of Liposomal Ciprofloxacin to Treat Lung Infections. Pharmaceutics. 2016. 8(1): 6. | Supplementary Material

 

Cipolla D. et al. Formation of Drug Nanocrystals under Nanoconfinement Afforded by Liposomes. RSC Advances. 2016. 6: 6223-6233.


Cipolla D. et al. Emerging Opportunities for Inhaled Antimicrobial Therapy. J Antimicro. 2015. 1(1): 104.


Cipolla D. et al. Aerosol Performance and Stability of Liposomes Containing Ciprofloxacin Nanocrystals. J Aer Med Pulm Drug Del. 2015. 28(6): 411-422.


Cipolla D. et al. Comment on: Inhaled antimicrobial therapy-Barriers to effective treatment. Adv. Drug Deliv. Rev. 2015. 85: e6-e7.


Norville IH. et al. Efficacy of liposome-encapsulated ciprofloxacin in a murine model of Q fever. Antimicrob Agents Chemother. 2014. 58: 5510-5518.


Cipolla D. et al. Aerosol Performance and Long Term Stability of Surfactant-Associated Liposomal Ciprofloxacin Formulations with Modified Encapsulation and Release Properties. AAPS PharmSciTech. 2014. 15(5): 1218-1227.


Hamblin KA. et al. The Potential of Liposome-Encapsulated Ciprofloxacin as a Tularemia Therapy. Front Cell Infect Microbiol. 2014. 4: 79


Cipolla D et al. Modifying the Release Properties of Liposomes toward Personalized Medicine. J. Pharm Sci. 2014. 103(6): 1851-1862.


Darweesh RS. And Sakagami M. In Vitro Inhibitory Activities of Liposomal Ciprofloxacin Against Lipopolysaccharide (LPS)-Induced IL-8 Release from the Calu-3 Cells. RDD 2014. Dalby R.N. et al. (eds). 2014. 747-750.


Cipolla D. et al. Development and Characterization of an In Vitro Release Assay for Liposomal Ciprofloxacin for Inhalation. J. Pharm. Sci. 2014. 103(1): 314-327.


Hamblin KA. Et al. Liposome encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis strain Schu S4. Antimicrob Agents Chemother. 2014. 58: 3053-3059.


Cipolla D et al. Liposomal Formulations for Inhalation. Ther Delivery. 2013. 4(8): 1047-1072.


Ong HX. et al. In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation. Eur J Pharm Biopharm. 2013. 86(1): 83-89.


Cipolla D. et al. Liposomal Ciprofloxacin for Inhalation Retains Integrity Following Nebulization. RDD Europe 2013. Dalby R.N. et al. (eds). 2013. 237-242.


Serisier DJ. Et al. Inhaled, Dual-Release Liposomal Ciprofloxacin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-2) – a Randomised, Double-Blind, Placebo-Controlled Trial. Thorax. 2013. 68(9): 812-817.


Ong HX. etal. Liposomal Nanoparticles Control the Uptake of Ciprofloxacin Across Respiratory Epithelia. Pharm Res. 2012. 29(12): 3335-3346.


Ong HX. et al. Inhaled Liposomal Ciprofloxacin Nanoparticles Control the Release of Antibiotic at the Bronchial Epithelia. RDD 2012. Dalby R.N. et al. (eds). 2012. 851-854.


Cipolla D et al. Liposomes, niosomes and proniosomes - a critical update of their (commercial) development as inhaled products. RDD Europe 2011. Dalby R.N. et al. (eds). 2011. 41-54.


Cipolla D. Et al. Inhaled Liposomal Ciprofloxacin: In Vitro Properties and Aerosol Performance. RDD 2010. Dalby R.N. et al. (eds). 2010. 409-414.


Bruinenberg P. et al. Inhaled liposomal ciprofloxacin: Once a day management of respiratory infections. RDD 2010. Dalby R.N. et al. (eds). 2010. 73-82.


Blanchard, J. Pulmonary Drug Delivery as a First Response to Bioterrorism. RDD X. Dalby R.N. et al. (eds). 2006. 73-82.


Yim D. et al. The development of inhaled liposome-encapsulated ciprofloxacin to treat cystic fibrosis. RDD X. Dalby R.N. et al. (eds). 2006. 425-428.

 

AERx® Technology
Cipolla D and Johansson E. AERx Pulmonary Drug Delivery Systems. Drugs and the Pharmaceutical Sciences, Modified Release Drug Delivery Technology. Second Edition. MJ Rathbone, J Hadgraft, MS Roberts, ME Lane (eds). Published by Informa Healthcare. 2008. 184: 563-572.


Gonda I. et al. Inhalation Delivery Systems with Compliance and Disease Management Capabilities. J Control Rel. 1998. 53:269-274.


Schuster J. et al. The AERx Aerosol Delivery System. Pharm Res. 1997. 14(3): 354-357.
Farr S.J. et al. AERx – Development of a Novel Liquid Aerosol Delivery System. RDD V. Dalby R.N. et al. (eds.) 1996. 175-184.

 

AERx® insulin Diabetes Management System
Aradigm scientists have published extensively on aerosol formulation and pulmonary drug delivery. Following are citations relating to insulin delivery.


Brunner, G.A. et al.: “Dose-Response Relation of Liquid Aerosol Inhaled Insulin in Type I Diabetic Patients” Diabetologia 1991; 44:305-308.


Cramer, J, Okikawa, J, and Cramer, J.: “Compliance with Inhaled Insulin Treatment Using AERx® insulin Diabetes Management System [Abstract]” Abstracts of Papers 63rd Annual Meeting of American Diabetes Association New Orleans, LA., 2003; Abstract #442.


Thippawong, J. et al.: “Pulmonary Insulin Administration Using the AERx® Insulin Diabetes System” Diabetes Technology & Therapeutics 2002; 4(4): 499-504.

 

Hermansen K, et al. Intensive Therapy With Inhaled Insulin via the AERx Insulin Diabetes Management System. 2004; 27(1); 162-7.


Brunner G.A. et al. Dose-Response Relation of Liquid Aerosol Inhaled Insulin in Type I Diabetic Patients. Diabetologia. 1991. 44: 305-308.


Farr, S. Efficiency of Inhaled Insulin Relative to Subcutaneous Insulin


McElduff, A et al. Influence of accute respiratory tract infection on the absorbtion unsing inhaled insulin using the AERx insulin Diabetes Management System. British JCP 2005; 1365-2125
.


Henry, RR et al. Inhaled Insulin Using the AERx Insulin Diabetes Management System in Healthy and Asthmatic Subjects 2003. 26(3):764-9
.


Dalby, RN et al. Respiratory Drug Delivery. 1998
.

 

Small Molecules delivered using the AERx inhaler
Cipolla D. and Gonda I. Inhaled Nicotine Replacement Therapy. Asian J Pharm Sci. 2015. 10(6): 472-480.


Gonda I. et al. Smoking Cessation Approach Via Deep Lung Delivery of ‘Clean’ Nicotine. RDD Europe 2009. Dalby R.N. et al. (eds). 2009. 57-62.


Cipolla D. et al. Development of an Inhaled AERx Essence Nicotine Product for Smoking Cessation. RDD 2008. Dalby R.N. et al. (eds). 2008. 365-369.


Chattopadhyay P. et al. Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. Adv Drug Del Rev. 2007. 59(6):444-453.


Shekunov B. et al. AERx Aerosol Properties of Drug-Lipid Nanosuspensions Produced using Supercritical Fluid Extraction of Emulsions (SFEE). RDD X. Dalby R.N. et al. (eds). 2006: 609-612.


Dayton F. et al. Development of an Inhaled Hydroxychloroquine Sulfate Product using the AERx System to Treat Asthma. RDD X. Dalby R.N. et al. (eds). 2006: 429-432.


Okumu F.W. et al. Evaluation of the AERx Pulmonary Delivery System for Systemic Delivery of a Poorly Soluble Selective D-1 Agonist, ABT-431. Pharm Res. 2002. 19(7): 1009-1012.


Deshpande D. et al. Development of an AERx System for Delivery of Bioscavengers. RDD IX. Dalby R.N. et al (eds). 2004: 349-351.


Cipolla D. et al. Bolus Administration of INS-365: Studying the Feasibility of delivering High Doses of Drug using the AERx Pulmonary Delivery System. RDD VII. Dalby R.N. et al. (eds). 2000. 231-239.


Derschwitz M. et al. Pharmacokinetics and Pharmacodynamics of Inhaled Versus Intravenous Morphine in Healthy Volunteers. Anesthesiology. 2000. 93(3): 619-628.


Chan H.K. et al. Deposition of Aqueous Aerosol of Technetium-99m Diethylene Triamine Penta-acetic Acid Generated and Delivered by a Novel System (AERx) in Healthy Subjects. Eur J Nuclear Medicine. 1999. 26(4): 320-37.


Mather L.E. et al. Pulmonary Administration of Aerosolized Fentanyl: Pharmacokinetic Analysis of Systemic Delivery. Br J Clin Pharmacol. 1998. 46:37-43.


Davison S. et al. Pharmacokinetics and acute safety of inhaled testosterone in postmenopausal women. J. Clin. Pharmacol. 2005. 45: 177-184.

 

Peptide and Protein Delivery using the AERx inhaler
Geller D. et al. Bolus Inhalation of rhDNase with the AERx System in Subjects with Cystic Fibrosis. J. Aerosol Med. 2003. 16(2): 175-182.

 

Thipphawong J. et al. Pulmonary Insulin Administration Using the AERx® Insulin Diabetes System. Diabetes Technology & Therapeutics. 2002. 4(4): 499-504.


Sangwan S. et al. Aerosolized Protein Delivery in Asthma: Gamma Camera Analysis of Regional Deposition and Perfusion. J. Aerosol Med. 2001. 14(2): 185-195.


Cipolla D. et al. Delivery of Biologics to the Lung. New Drugs for Asthma, Allergy and COPD. TT Hansel and PJ Barnes (eds). Published by S. Karger AG, Basel, Switzerland. 2001. 30: 20-23.

 

Mudumba S. et al. Delivery of rhDNase Using the AERx® Pulmonary Delivery System. RDD VII. Dalby R.N. et al. (eds). 2000. 329-332.


Brunner G.A. et al. Dose-Response Relation of Liquid Aerosol Inhaled Insulin in Type I Diabetic Patients. Diabetologia. 1991. 44: 305-308.

 

Gene Therapy using the AERx inhaler
Deshpande D. et al. Gamma scintigraphic evaluation of a miniaturized AERx Pulmonary Delivery System for aerosol delivery to anesthetized animals using a positive pressure ventilation system. J. Aerosol Med. 2005. 18: 34-44.


Mudumba S. et al. Non-Viral Delivery of COX-1 Gene by the Pulmonary Delivery System. RDD IX. Dalby R.N. et al. (eds). 2004. 353-355.


Desphande D. et al. Aerosolization of Lipoplexes Using AERx® Pulmonary Delivery System. AAPS PharmSci. 2002. 4(3): 1-10.

 

CONTACT NEWS & EVENTS LEGAL SITE MAP

©2016 Aradigm Corporation. All Rights Reserved.